Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Regulatory Affairs

Executive Summary

FDA Office of Enforcement Acting Director Steven Niedelman will become assistant commissioner for regulatory affairs, a new position, as of Dec. 1. Niedelman has been acting head of enforcement since September, after joining the office as deputy director in July 2001 (1"The Pink Sheet" Sept. 16, p. 23). He previously spent 24 years in the Center for Devices & Radiologic Health's compliance office. Niedelman will continue to report to Associate Commissioner for Regulatory Affairs John Taylor...

You may also be interested in...



FDA Enforcement Office Director Niedelman Brings CDRH Background To Post

The FDA Office of Enforcement's transition to "risk-based" good manufacturing practices oversight will be led by an FDAer with more than two decades of experience in medical device manufacturing regulation

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel